07. April 2015 William R. Gruver agrees to lead INDIVUMED business advisory team

Past General Partner and Chief Administrative Officer of the Equities Division of Goldman, Sachs & Co. and current member of the Board of Directors of the Pennsylvania-based Geisinger Health System will advise Indivumed, GmbH and its affiliates during the company’s global expansion campaign. Hartmut Juhl, MD, President and Chief Executive Officer of Indivumed, GmbH, announced today that William R. Gruver, the Howard I. Scott Chair in Global Commerce, Strategy, and Leadership at Bucknell University, will chair the Indivumed, GmbH Business Advisory Committee, assisting in the development and implementation of a transformational expansion of the company's global oncology research network. Professor Gruver, an international strategic consultant for businesses in the U.S., Europe, and Asia, also serves on the boards of Hirtle, Callaghan & Co., a USD 25 billion investment firm, and Geisinger Health System, one of the foremost nationally recognized integrated health systems in the United States. He also serves as a national arbitrator for the Financial Industry Regulatory Authority (FINRA). When asked to comment, Dr. Juhl said of Professor Gruver: "Bill brings to INDIVUMED an international business perspective that will allow our company to grow within our three target markets, the United States, Europe, and Asia." Juhl went on to say, "The fuel for our growth will come largely from venture investments. Bill understands this world, and I will rely heavily on his judgment and perspective." When contacted, Gruver stated of this new collaboration: "INDIVUMED is ideally positioned at the junction of opportunity and competence. The biomedical research market is responding quickly and generously to the acquisition and analysis of high quality data to attack the catastrophic failure rates of new drugs, particularly in cancer. INDIVUMED has perfected, over the past 12 years, the practice of securing high quality tissue and data in a manner far advanced over their competitors." He continued by stating that: "Hartmut and his team represent a world class cancer biologics company, built on German precision and commitment to excellence. I am excited and honored to be a part of this unique team."

Press contact:

Indivumed GmbH
Swantje Niphut
Marketing Communications Manager
Tel.: +49-40-4133-8375
E-mail: press@indivumed.com www.indivumed.com